Pfizer (PFE) Net Margin (2009 - 2026)

Pfizer (PFE) has reported Net Margin for 18 consecutive years, with 1.58% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Margin fell 2157.0% year-over-year to 1.58% in Q2 2026; TTM through Jun 2026 was 6.86%, a 866.0% decrease from a year earlier, with the FY2025 full-year figure at 12.48%, down 19.0% from the prior year.
• Net Margin was 1.58% for Q2 2026 at Pfizer, down from 18.66% in the prior quarter.
• Over five years, Net Margin peaked at 35.73% in Q3 2022 and troughed at 97.85% in Q4 2023.
• A 5-year average of 8.95% and a median of 19.32% in 2025 frame the typical range for Net Margin.
• Across the five-year window, Net Margin soared 1962 bps in 2025 and slumped 2157 bps in 2026, its largest moves.
• Over 5 years, Net Margin stood at 35.73% in 2022, then tumbled by 374 bps to 97.85% in 2023, then jumped by 117 bps to 16.64% in 2024, then sank by 156 bps to 9.34% in 2025, then jumped by 83 bps to 1.58% in 2026.
• The last three Net Margin figures came in at 1.58% (Q2 2026), 18.66% (Q1 2026), and 9.34% (Q4 2025), per Business Quant data.